News

Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia

June 4, 2019- Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has been dosed with its lead candidate, leriglitazone (MIN-102), in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia.

| Read more |

Competitive Intelligence Startup Kompyte Raises $3M and Expands Operations in Austin, Texas

Caixa Capital Risc, Adara Ventures and Swanlaab Venture Factory, along with other existing investors are the funders.
The company provides revolutionary software that automates competitive research and reporting, so their customers can monitor competitors in real-time and adjust their strategy to best compete.

| Read more |

Sheetgo closes a round led by Caixa Capital Risc to finance the launch of its new platform [Article in Spanish]

The start-up, specialized in creating workflows from spreadsheets, will launch its new platform. It already reaches half a million users online and captures one million dollars to keep growing.

| Read more |

Minoryx Therapeutics appoints Didier Le Normand as Group Chief Financial Officer (CFO) and General Manager of its Belgian subsidiary

Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has appointed Mr. Didier Le Normand as Group CFO as well as General Manager of its recently opened Belgian subsidiary.

| Read more |

Minoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s Ataxia.

FRAMES trial expected to initiate patient recruitment in upcoming weeks in Spain, Belgium and other European countries.
Two Key Opinion Leaders join Minoryx’s scientific advisory board.
In 2018 Minoryx closed a Series B funding round of €21.3M to expand the development of MIN-102 into new indications.

| Read more |